Larvol Delta - IL13-inhibition-in-the-treatment-of-atopic-dermatitis--new-and-emerging-biologic-agents

cendakimab (CC-93538) - AbbVie, BMS

Ebglyss (lebrikizumab-lbkz) - Eli Lilly

Adbry (tralokinumab-ldrm) - LEO Pharma, AstraZeneca

eblasakimab (ASLAN004) - ASLAN Pharma, Zenyaku Holdings

http://www.ncbi.nlm.nih.gov/pubmed/39558725

Carlos Teixeira; Diana Bernardo; Orhan Yilmaz; Tiago Torres

Nov 19, 2024